Literature DB >> 1096801

Rapid, simple bioassay for 5-fluorocytosine in the presence of amphotericin B.

R L Kaspar, D J Drutz.   

Abstract

It is important that serum levels of 5-fluorocytosine (5FC) be measured to insure therapeutic levels while avoiding toxicity. This is particularly true in patients with renal insufficiency. The concurrent use of amphotericin B and 5FC complicates the measurement of 5FC in the serum, since fungi used in conventional bioassay systems are uniformly susceptible to amphotericin B. This paper describes the development of a simple, reliable, 6-h bioassay for 5FC in the presence of amphotericin B. The assay is based upon the fact that 5FC diffuses readily through yeast nitrogen base agar, whereas amphotericin B apparently does not. This assay allows rapid adjustments in therapy of patients receiving both 5FC and amphotericin B and has permitted us to maintain 5FC serum levels between limits of 25 and 120 mug/ml in patients with altered renal function.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1096801      PMCID: PMC429163          DOI: 10.1128/AAC.7.4.462

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  20 in total

1.  Effect of 5-fluorocytosine and amphotericin B on Candida albicans infection in mice.

Authors:  S Rabinovich; B D Shaw; T Bryant; S T Donta
Journal:  J Infect Dis       Date:  1974-07       Impact factor: 5.226

2.  The kinetics of 5-fluorocytosine elimination in man.

Authors:  D N Wade; G Sudlow
Journal:  Aust N Z J Med       Date:  1972-05

3.  Flucytosine and amphotericin B: hemodialysis effects on the plasma concentration and clearance. Studies in man.

Authors:  E R Block; J E Bennett; L G Livoti; W J Klein; R R MacGregor; L Henderson
Journal:  Ann Intern Med       Date:  1974-05       Impact factor: 25.391

4.  Pharmacokinetic studies on the oral antimycotic agent 5-fluorocytosine in individuals with normal and impaired kidney function.

Authors:  J Schönebeck; A Polak; M Fernex; H J Scholer
Journal:  Chemotherapy       Date:  1973       Impact factor: 2.544

5.  Development of resistance to 5-fluorocytosine in Candida parapsilosis during therapy.

Authors:  P D Hoeprich; J L Ingraham; E Kleker; M J Winship
Journal:  J Infect Dis       Date:  1974-08       Impact factor: 5.226

6.  Treatment of disseminated candidiasis with 5-fluorocytosine.

Authors:  T Eilard; K Alestig; P Wahlén
Journal:  J Infect Dis       Date:  1974-08       Impact factor: 5.226

7.  Anti-Candida factors in serum and their inhibitors. I. Clinical and laboratory observations.

Authors:  D B Louria; J K Smith; R G Brayton; M Buse
Journal:  J Infect Dis       Date:  1972-02       Impact factor: 5.226

8.  Pharmacological studies with 5-fluorocytosine.

Authors:  E R Block; J E Bennett
Journal:  Antimicrob Agents Chemother       Date:  1972-06       Impact factor: 5.191

9.  In vitro studies of 5-fluorocytosine resistance in Candida albicans and Torulopsis glabrata.

Authors:  S Normark; J Schönebeck
Journal:  Antimicrob Agents Chemother       Date:  1972-09       Impact factor: 5.191

10.  Variables influencing susceptibility testing of Cryptococcus neoformans to 5-fluorocytosine.

Authors:  E R Block; A E Jennings; J E Bennett
Journal:  Antimicrob Agents Chemother       Date:  1973-10       Impact factor: 5.191

View more
  17 in total

1.  Rapid determination of serum 5-fluorocytosine levels by high-performance liquid chromatography.

Authors:  R B Diasio; M E Wilburn; S Shadomy; A Espinel-Ingroff
Journal:  Antimicrob Agents Chemother       Date:  1978-03       Impact factor: 5.191

2.  Rapid determination of 5-fluorocytosine levels in blood.

Authors:  M A Noble; B Harper; A G Grant; M Bernstein
Journal:  J Clin Microbiol       Date:  1984-11       Impact factor: 5.948

3.  Improved procedure for determination of flucytosine in human blood plasma by high-pressure liquid chromatography.

Authors:  U Schwertschlag; L M Nakata; J Gal
Journal:  Antimicrob Agents Chemother       Date:  1984-09       Impact factor: 5.191

Review 4.  Clinical pharmacokinetics of systemic antifungal drugs.

Authors:  T K Daneshmend; D W Warnock
Journal:  Clin Pharmacokinet       Date:  1983 Jan-Feb       Impact factor: 6.447

5.  Pharmacology and toxicity of high-dose ketoconazole.

Authors:  A M Sugar; S G Alsip; J N Galgiani; J R Graybill; W E Dismukes; G A Cloud; P C Craven; D A Stevens
Journal:  Antimicrob Agents Chemother       Date:  1987-12       Impact factor: 5.191

Review 6.  Treatment of systemic fungal infections: recent progress and current problems.

Authors:  T J Walsh; A Pizzo
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1988-08       Impact factor: 3.267

7.  Simple assay for 5-fluorocytosine in the presence of amphotericin B.

Authors:  C A Kauffman; J A Carleton; P T Frame
Journal:  Antimicrob Agents Chemother       Date:  1976-03       Impact factor: 5.191

8.  Interaction of chemotherapy and immune defenses in experimental murine cryptococcosis.

Authors:  J R Graybill; P C Craven; L F Mitchell; D J Drutz
Journal:  Antimicrob Agents Chemother       Date:  1978-11       Impact factor: 5.191

9.  Assay of flucytosine (5-fluorocytosine) in human plasma by high-pressure liquid chromatography.

Authors:  R W Bury; M L Mashford; H M Miles
Journal:  Antimicrob Agents Chemother       Date:  1979-11       Impact factor: 5.191

10.  Cryptococcal meningitis complicating systemic lupus erythematosus: two patients treated with flucytosine and amphotericin B.

Authors:  D C Speller; F Fakunle; S A Cairns; M Stephens
Journal:  J Clin Pathol       Date:  1977-03       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.